In 2010, Vatera Healthcare Partners joined Pearl as a fourth investor. Spokeswoman Alisha Martin said the leasing arrangement resulted from “organic growth in (Pearl’s) production of inhaled small-molecule therapeutics for respiratory disease.” She said the company uses both in-house and contract manufacturing for its development pipeline. Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD - Results Confirm Glycopyrrolate Twice-Daily Dosing - REDWOOD CITY, Calif., Dec. 7, 2011 /PRNewswire/ -- Pearl Upon completion of the merger, AstraZeneca acquired 100% of Pearl’s shares. We encourage you to read the privacy policy of every website you visit.AstraZeneca's work environment is dynamic and fosters innovation. Our company Our strategy Our people Leadership team Careers . Pearl Huang is a venture partner at Flagship Pioneering and chief executive officer and director of Cygnal Therapeutics.She is also on the board of KSQ Therapeutics.. Before joining Flagship, Pearl most recently served as senior vice president and global head of therapeutic modalities at Roche, where she oversaw the discovery of biologic, small molecule, and nucleic acid-based therapies. AstraZeneca acquired Pearl in July 2013. Pearl is rapidly advancing a pipeline of products … ... including chronic obstructive pulmonary disease and asthma. It also has a site in New Jersey. Pipeline Publications Cambridge Gothenburg Gaithersburg Our therapy areas. AstraZeneca provides this link as a service to website visitors. Pearl, which is now a member of the AstraZeneca Group, was founded in 2006, with a mission and vision to develop differentiated therapeutics for widely prevalent respiratory disease conditions, including chronic obstructive pulmonary disease (COPD), by utilising a proprietary drug delivery platform and existing therapeutic agents administered in metered-dose inhalers (MDIs).
As part of the AstraZeneca Group, we will continue the ongoing commitment to progress developments and innovation in respiratory science.Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. About Pearl Therapeutics. “We’re able to attract and retain great employees, which is the foundation of Pearl’s success.”“The company expects continued hiring over the next year to support its research and development programs,” she added.The company currently has about 100 employees developing inhaled combination therapies to treat such respiratory diseases as chronic obstructive pulmonary disease and asthma, using metered dose inhalers. Each location conducts similar activities, said Martin. Investor Relations (Global) About Pearl Therapeutics, Inc. Pearl is developing a portfolio of meaningfully differentiated products to treat respiratory diseases including COPD and asthma.